# Hypopituitarism and Pituitary Apoplexy

## Hypopituitarism - Definition and Etiology

### Overview

Hypopituitarism refers to the partial or complete deficiency of one or more anterior pituitary hormones, and may include posterior pituitary dysfunction manifesting as diabetes insipidus. When all anterior pituitary hormones are deficient, the condition is termed panhypopituitarism. The prevalence of hypopituitarism is estimated at approximately 45 per 100,000, with an incidence of 4 per 100,000 per year. Despite the availability of hormone replacement therapy, patients with hypopituitarism carry an increased standardized mortality ratio of 1.2 to 2.2, primarily attributable to cardiovascular disease and adrenal crises. Adequate hormone replacement improves outcomes but may not fully normalize mortality, underscoring the difficulty of perfectly replicating physiological hormone dynamics with exogenous therapy.

### Etiologies

The causes of hypopituitarism are diverse and can be organized by pathophysiological mechanism. Pituitary adenomas represent the most common cause in adults, producing hypopituitarism through mass effect on normal pituitary tissue and, in many cases, through the additional insult of surgical intervention. Pituitary surgery carries a risk of new hormone deficits proportional to tumor size and inversely related to surgical experience, with new deficiencies developing in 5 to 15% of patients following transsphenoidal surgery.

Radiation therapy to the pituitary or surrounding structures causes progressive, dose-dependent pituitary damage that may evolve over years to decades. GH is the most radiation-sensitive axis, with deficiency developing in more than 75% of patients at 5 years when doses exceed 30 Gy. Gonadotropins are the next most vulnerable, followed by ACTH and finally TSH.

Traumatic brain injury (TBI) has emerged as an increasingly recognized cause of hypopituitarism, with prevalence estimates of 15 to 50% depending on injury severity. GH and gonadotropin deficiencies are the most commonly identified deficits. Current guidelines recommend screening at 3 to 6 months and again at 12 months following moderate to severe TBI. Subarachnoid hemorrhage produces pituitary damage through a similar mechanism, with 35 to 50% of survivors demonstrating at least one pituitary hormone deficiency.

Sheehan syndrome, resulting from postpartum pituitary necrosis secondary to hemorrhagic shock during delivery, classically presents with failure of lactation, persistent amenorrhea, and progressive fatigue. While increasingly rare in developed countries with modern obstetric care, it remains an important cause of hypopituitarism in resource-limited settings.

Lymphocytic hypophysitis is an autoimmune condition that predominantly affects women, with a particular predilection for the peripartum period. It can affect specific cell types, giving rise to adenohypophysitis, infundibuloneurohypophysitis, or panhypophysitis. Importantly, lymphocytic hypophysitis is now recognized as a complication of immune checkpoint inhibitor (ICI) therapy. Ipilimumab, an anti-CTLA-4 antibody, causes hypophysitis in 5 to 17% of treated patients, while anti-PD-1 and anti-PD-L1 agents more commonly cause isolated ACTH deficiency or primary thyroiditis rather than full hypophysitis. A critical clinical point is that ACTH recovery following ICI-induced hypophysitis is rare, occurring in only about 4% of patients, necessitating lifelong glucocorticoid replacement.

Infiltrative and granulomatous diseases, including sarcoidosis, Langerhans cell histiocytosis, hemochromatosis, and granulomatosis with polyangiitis (formerly Wegener granulomatosis), can involve the hypothalamic-pituitary region. Hemochromatosis particularly affects somatotrophs and gonadotrophs, reflecting the selective iron deposition in these cell types. Infectious causes include tuberculosis, fungal infections such as histoplasmosis and aspergillosis, and pituitary abscesses.

Genetic causes of hypopituitarism span a growing list of transcription factor mutations. PROP1 mutations are the most common genetic cause of combined pituitary hormone deficiency, producing deficiencies of GH, prolactin, TSH, LH, and FSH with occasional late-developing ACTH loss. Other causative genes include PIT1/POU1F1, HESX1, LHX3, LHX4, TPIT, GH1, GHRHR, KISS1R, GnRHR, and KAL1.

Empty sella, whether primary (idiopathic) or secondary to surgery, radiation, or infarction, may or may not be associated with pituitary dysfunction, and functional testing is required to determine hormonal status. Craniopharyngiomas are benign but locally aggressive tumors that arise from Rathke pouch remnants, with two histological subtypes: adamantinomatous (occurring primarily in children and harboring CTNNB1 mutations) and papillary (occurring in adults with BRAF V600E mutations). These tumors carry a high recurrence rate and frequently cause hypothalamic obesity following treatment. Metastatic disease to the pituitary most commonly originates from breast and lung primaries and has a predilection for the posterior pituitary and stalk, making diabetes insipidus more common than anterior pituitary deficiency in this setting.

<image>A comprehensive infographic illustrating the etiologies of hypopituitarism organized by mechanism. Arrange in a circular diagram around a central pituitary gland image. Categories include: Mass lesions (adenoma, craniopharyngioma, Rathke cleft cyst, meningioma, metastasis), Vascular (apoplexy, Sheehan syndrome, aneurysm), Inflammatory/Autoimmune (lymphocytic hypophysitis, ICI-induced, IgG4, sarcoidosis), Infectious (TB, fungal, abscess), Iatrogenic (surgery, radiation), Traumatic (TBI, SAH), Infiltrative (hemochromatosis, LCH), and Genetic (PROP1, PIT1, HESX1). Use distinct color coding for each category.</image>

## Order of Hormone Loss

### Typical Sequence Following Radiation or Compression

The anterior pituitary hormones exhibit a characteristic hierarchy of vulnerability to damage from radiation or compression, a pattern that has important implications for both diagnosis and surveillance. GH is the most vulnerable hormone, with somatotrophs demonstrating the greatest sensitivity to radiation injury and compressive damage. Gonadotropins (LH and FSH) are the next to be affected, followed by TSH, and finally ACTH, which is relatively resistant and typically the last anterior pituitary hormone to be lost. A useful mnemonic for this sequence is "Go Look For The Adenoma," representing GH, LH/FSH, TSH, and ACTH in order of vulnerability.

Prolactin follows a different pattern, being typically the last anterior hormone to become truly deficient. More commonly, prolactin levels are elevated rather than decreased due to the stalk effect, making hyperprolactinemia a more frequent finding than prolactin deficiency. Posterior pituitary function (vasopressin/ADH) is rarely affected by pituitary adenomas alone but is more commonly disrupted by craniopharyngiomas, metastatic disease, infiltrative processes, or surgical intervention.

### Exceptions

Several important exceptions to this typical sequence merit recognition. In lymphocytic hypophysitis, ACTH deficiency may occur early or in isolation, reversing the usual hierarchy. ICI-induced hypophysitis commonly produces ACTH and TSH deficiency while often preserving GH secretion. TPIT mutations cause isolated ACTH deficiency as a primary genetic disorder. In pituitary apoplexy, any combination of deficiencies may occur acutely and simultaneously, without following the typical sequential pattern.

## Diagnosis of Hypopituitarism

### Basal Testing

The diagnostic evaluation of hypopituitarism begins with basal hormone measurements, always interpreted in pairs consisting of the pituitary hormone and its corresponding target gland hormone.

For the cortisol axis, a morning cortisol drawn between 08:00 and 09:00 provides the most informative basal measurement. A value below 3 mcg/dL is essentially diagnostic of cortisol deficiency, while a value above 15 to 18 mcg/dL generally excludes the diagnosis. Intermediate values require dynamic testing for definitive assessment. Simultaneous ACTH measurement helps distinguish primary adrenal insufficiency (elevated ACTH) from secondary or tertiary insufficiency (low or inappropriately normal ACTH).

For the thyroid axis, free T4 and TSH should be measured together. A low free T4 with a low, normal, or even mildly elevated TSH indicates central hypothyroidism. The TSH in central hypothyroidism may be "normal" in numerical terms but is biologically inappropriate for the degree of thyroid hormone deficiency. Importantly, TSH is unreliable for monitoring the adequacy of levothyroxine replacement in central hypothyroidism; free T4 must be used instead.

For the gonadal axis, LH, FSH, and sex steroids (morning testosterone in males, estradiol in females) should be assessed simultaneously. Low sex steroids with low or inappropriately normal gonadotropins establish the diagnosis of central hypogonadism. In premenopausal women, oligomenorrhea or amenorrhea is often the most sensitive clinical indicator of gonadotropin deficiency.

For the GH axis, IGF-1 serves as a useful screening test, with a low value for age being suggestive of GH deficiency. However, a normal IGF-1 does not exclude GH deficiency, and dynamic testing is required for definitive diagnosis. Prolactin levels that are low suggest severe hypopituitarism affecting lactotrophs, while elevated levels suggest either the stalk effect or a prolactinoma. Posterior pituitary assessment involves measurement of serum sodium, urine osmolality, and serum osmolality, with a water deprivation test performed when diabetes insipidus is suspected.

### Dynamic Testing for ACTH Axis

The insulin tolerance test (ITT) is considered the gold standard for ACTH axis assessment. Regular insulin is administered intravenously at a dose of 0.1 to 0.15 U/kg to induce adequate hypoglycemia (blood glucose below 40 mg/dL). A peak cortisol response exceeding 18 to 20 mcg/dL excludes adrenal insufficiency. The ITT is contraindicated in patients with seizure disorders, coronary artery disease, the elderly, and those with a baseline cortisol below 5 mcg/dL, and requires continuous physician supervision.

The standard-dose cosyntropin stimulation test (250 mcg) assesses adrenal cortisol reserve by measuring the peak cortisol response at 30 and 60 minutes, with a value exceeding 18 mcg/dL considered normal. A crucial limitation is that this test may yield falsely normal results in acute or recent-onset secondary adrenal insufficiency, because adrenal cortical atrophy from ACTH deprivation requires 4 to 6 weeks to develop. The low-dose cosyntropin test (1 mcg) offers greater sensitivity for detecting partial secondary adrenal insufficiency but is technically more challenging due to the dilution requirements and potential for drug adherence to plastic tubing.

The overnight metyrapone test and the glucagon stimulation test provide additional alternatives. The glucagon test, using 1 mg administered intramuscularly, has the advantage of simultaneously assessing both GH and cortisol reserve, making it an efficient alternative when the ITT is contraindicated.

### Dynamic Testing for GH Axis

In adults, dynamic testing is required for the diagnosis of GH deficiency, as a low IGF-1 alone is insufficient to establish the diagnosis. The sole exception is the patient with panhypopituitarism who has three or more other documented deficiencies and a low IGF-1, in whom the pretest probability is sufficiently high to render dynamic testing unnecessary.

The ITT remains the reference standard, with a GH peak exceeding 5 ng/mL (some authorities use 3 ng/mL) excluding GH deficiency. The glucagon stimulation test (GST) serves as the preferred alternative, with a GH peak above 3 ng/mL considered normal, though lower cutoffs apply in obese individuals (above 1 ng/mL). The macimorelin test, an oral GH secretagogue, has received FDA approval for diagnosing adult GH deficiency. A GH peak above 2.8 ng/mL after oral administration of 0.5 mg/kg excludes the diagnosis. This test offers significant practical advantages in terms of convenience and patient comfort, though caution is warranted with concomitant medications that affect CYP3A4 metabolism or the QTc interval.

## Hormone Replacement Therapy

### Cortisol Replacement (Priority #1)

| Axis | Replacement | Dose | Monitoring | Key Notes |
|---|---|---|---|---|
| Cortisol (Priority #1) | Hydrocortisone | 15-25 mg/day divided BID-TID | Clinical (no reliable lab test) | Stress dosing essential; start BEFORE T4 |
| | Prednisolone (alternative) | 3-5 mg/day QD-BID | Clinical | Longer half-life, simpler dosing |
| | Plenadren (modified-release HC) | 20 mg QAM | Clinical | Mimics diurnal rhythm; costly |
| Thyroid (Priority #2) | Levothyroxine | 1.0-1.6 mcg/kg/day | Free T4 (NOT TSH) | Target free T4 upper half of normal |
| Sex steroids | Testosterone (males) | Gel 50-100 mg/day or IM 100-200 mg q1-2 wk | Testosterone levels, hematocrit | Does NOT restore fertility |
| | Estrogen (females) | Transdermal estradiol preferred | Clinical | Gonadotropins needed for fertility |
| GH | Somatropin | Start 0.2-0.4 mg/day SC | IGF-1 (mid-normal for age) | Women on oral estrogen need higher doses |
| ADH (if DI) | Desmopressin | Oral 0.1-0.4 mg BID-TID or intranasal 5-20 mcg BID | Serum sodium | Allow weekly breakthrough polyuria |

Glucocorticoid replacement represents the highest priority in hypopituitarism management, as cortisol deficiency poses the most immediate threat to life. Hydrocortisone is the most commonly used preparation, administered at a total daily dose of 15 to 25 mg divided into two or three doses. A typical regimen is 10 mg upon waking, 5 mg at midday, and 5 mg in the late afternoon, attempting to approximate the physiological diurnal cortisol rhythm. Weight-based dosing of approximately 0.2 to 0.3 mg/kg/day helps guide initial prescribing.

Alternative glucocorticoid preparations include cortisone acetate at 25 to 37.5 mg daily, which requires hepatic conversion by 11-beta-hydroxysteroid dehydrogenase type 1, and prednisolone at 3 to 5 mg daily in one or two doses, which offers the convenience of a longer half-life and the possibility of once-daily dosing. Modified-release hydrocortisone (Plenadren), administered as a single 20 mg morning dose, more closely mimics the physiological cortisol diurnal rhythm and has shown reduced metabolic side effects in some studies, though its higher cost limits widespread adoption.

Stress dosing is an essential component of glucocorticoid replacement that patients and their caregivers must thoroughly understand. The standard recommendation is to double or triple the oral dose during febrile illness, and to administer intramuscular or intravenous hydrocortisone at 50 to 100 mg for vomiting, significant surgical procedures, or severe illness. All patients must carry an emergency injection kit and wear medical alert identification. A critical management principle is that cortisol replacement must always be initiated before thyroid hormone replacement, because levothyroxine increases cortisol metabolism and may precipitate an adrenal crisis in an unprotected patient.

There is no reliable laboratory test to monitor the adequacy of glucocorticoid dosing. Clinical assessment, including monitoring of weight, energy levels, blood pressure, and symptoms of both under- and over-replacement, guides dose adjustments. Over-replacement carries metabolic consequences including features of Cushing syndrome, metabolic syndrome, and accelerated bone loss.

### Thyroid Hormone Replacement

Levothyroxine is the treatment of choice for central hypothyroidism, dosed at approximately 1.0 to 1.6 mcg/kg/day with the goal of maintaining free T4 in the upper half of the normal reference range. Monitoring must rely on free T4 measurements rather than TSH, which is unreliable in central hypothyroidism. Free T4 should be reassessed 6 to 8 weeks after any dose adjustment. Thyroid replacement must be initiated only after glucocorticoid replacement has been established, to avoid precipitating an adrenal crisis.

### Sex Steroid Replacement

In males with central hypogonadism, testosterone replacement is administered via topical gel (1% formulation, 50 to 100 mg daily), intramuscular injection (testosterone cypionate or enanthate, 100 to 200 mg every 1 to 2 weeks), or long-acting testosterone undecanoate (750 mg intramuscularly every 10 weeks following a loading schedule). In premenopausal females, estrogen replacement is provided through combined oral contraceptive pills or hormone replacement therapy, with transdermal estradiol preferred due to its lower venous thromboembolism risk compared to oral preparations. An essential counseling point is that standard sex steroid replacement does not restore fertility. Patients desiring fertility require gonadotropin therapy (hCG with FSH in males; FSH with hCG or LH in females) or pulsatile GnRH administration to stimulate gonadal function and gametogenesis.

### Growth Hormone Replacement

GH replacement is indicated for adults with confirmed GH deficiency who demonstrate impaired quality of life, regardless of other pituitary hormone deficits. Starting doses are 0.2 to 0.4 mg/day subcutaneously in younger adults and 0.1 to 0.2 mg/day in older adults. Women receiving oral estrogen require higher GH doses due to the first-pass hepatic effect that suppresses IGF-1 production. Dose titration is performed in increments of 0.1 to 0.2 mg every 4 to 6 weeks, with the goal of normalizing IGF-1 to the mid-normal range for age and sex.

Long-acting GH formulations, including somapacitan and lonapegsomatropin (both FDA-approved for adults and administered weekly), offer improved convenience and adherence. The benefits of GH replacement include improved body composition with reduced visceral fat and increased lean mass, enhanced bone mineral density, improved quality of life and exercise capacity, and favorable lipid profile changes. Monitoring includes IGF-1 levels, fasting glucose (given GH's diabetogenic properties), lipids, and body composition. Contraindications include active malignancy, active proliferative diabetic retinopathy, and benign intracranial hypertension.

### Desmopressin (for Central DI)

Desmopressin (DDAVP), a synthetic vasopressin analog with selective V2 receptor activity, is the treatment of choice for central diabetes insipidus. It is available in oral (0.1 to 0.4 mg twice to three times daily), intranasal (5 to 20 mcg twice daily), and sublingual (60 to 120 mcg twice to three times daily) formulations. The dose is titrated to control polyuria and normalize serum sodium, with the ongoing risk of hyponatremia from over-replacement requiring vigilant monitoring. A practical management strategy is to allow breakthrough polyuria at least once weekly, creating a brief "escape" window that prevents progressive water retention and dilutional hyponatremia.

<image>A treatment priority pyramid for hypopituitarism hormone replacement. At the base (highest priority, labeled "Replace FIRST"): glucocorticoid replacement with hydrocortisone 15-25 mg/day shown with a red emergency banner and stress-dose instructions. Second level: levothyroxine (start AFTER glucocorticoid established). Third level: sex steroids (testosterone or estrogen/progesterone) with a note about gonadotropins for fertility. At the top: growth hormone replacement. On the side, show desmopressin for DI if present. Include key monitoring parameters for each level. Use a clean pyramid infographic style with distinct colors for each tier.</image>

## Pituitary Apoplexy

### Definition and Pathophysiology

Pituitary apoplexy is a clinical syndrome resulting from acute hemorrhage and/or infarction within a pituitary adenoma, although it can rarely occur in a normal gland. The syndrome is characterized by the sudden onset of severe headache, visual disturbance, cranial nerve palsies, altered consciousness, and hormonal deficiency. It is important to distinguish clinical apoplexy from subclinical apoplexy, which refers to hemorrhagic or ischemic changes identified on imaging without an accompanying acute clinical syndrome. Subclinical apoplexy is considerably more common, found in 15 to 25% of pituitary adenomas on MRI, whereas true clinical apoplexy occurs in only approximately 2 to 7% of pituitary adenomas.

### Precipitating Factors

While many cases of pituitary apoplexy occur spontaneously without an identifiable trigger, several precipitating factors have been recognized. Anticoagulation therapy is the most commonly identified risk factor. Major surgery, particularly cardiac procedures requiring anticoagulation, represents another important predisposing condition. Less common triggers include dynamic pituitary testing with CRH, GnRH, or TRH (a rare but recognized complication), dopamine agonist therapy (which can cause acute hemorrhage into a prolactinoma), pregnancy (unmasking a previously undiagnosed adenoma), and chronic conditions such as diabetes mellitus, hypertension, head trauma, and prior radiation therapy.

### Clinical Presentation

The hallmark of pituitary apoplexy is the sudden onset of severe headache, typically described as retro-orbital or frontal, that mimics subarachnoid hemorrhage and demands urgent differentiation from this diagnosis. Visual deficits occur in 60 to 80% of patients, manifesting as bitemporal hemianopia or other field defects, with decreased visual acuity indicating more severe optic nerve compromise. Ophthalmoplegia from compression of cranial nerves within the cavernous sinus is present in a large proportion of cases, with cranial nerve III being affected in 40 to 70%, cranial nerve VI in 20 to 30%, and cranial nerve IV less commonly involved. The palsy is typically unilateral.

Altered consciousness, ranging from confusion to coma, occurs in 15 to 20% of patients and suggests severe compression of surrounding neural structures or subarachnoid hemorrhage extension. Meningism may result from blood or necrotic tissue entering the subarachnoid space. Acute adrenal insufficiency is present in 60 to 80% of patients at presentation and represents the most immediately life-threatening complication, manifesting with hypotension and hyponatremia. Central hypothyroidism and hypogonadism frequently accompany the presentation, while diabetes insipidus is uncommon in the acute setting of apoplexy.

### Differential Diagnosis

The differential diagnosis of pituitary apoplexy includes subarachnoid hemorrhage (the most critical alternative to exclude), ruptured intracranial aneurysm, bacterial meningitis, cavernous sinus thrombosis, and midbrain infarction. The clinical overlap with subarachnoid hemorrhage is substantial, and imaging is essential for differentiation.

### Diagnostic Evaluation

CT of the head is often the first imaging study obtained given the acute presentation and may demonstrate hemorrhage as a hyperintense signal within the sella. However, CT can be normal if the apoplexy is predominantly ischemic or subacute. MRI of the pituitary is the gold standard, revealing T1 hyperintensity in acute to subacute hemorrhage, fluid-fluid levels within the sella, and ring enhancement. Hormonal evaluation, including a STAT cortisol, electrolytes, free T4, TSH, and prolactin, should be obtained promptly, but treatment must not be delayed pending laboratory results when the clinical suspicion is high. Lumbar puncture should be performed only if subarachnoid hemorrhage cannot be excluded by imaging and is generally deferred when MRI is diagnostic.

### Management

#### Acute Medical Management

The cornerstone of acute management is the immediate administration of intravenous glucocorticoids. Hydrocortisone should be given as a 100 mg intravenous bolus followed by 50 to 100 mg intravenously every 6 to 8 hours. This treatment should not be delayed while awaiting cortisol results, as the risk of untreated adrenal insufficiency in this setting is potentially fatal. Concurrent measures include intravenous fluid resuscitation with isotonic saline, correction of hyponatremia, close neurological monitoring of visual acuity, visual fields, pupillary responses, and level of consciousness every 4 to 6 hours, electrolyte monitoring for both DI and SIADH, and hemodynamic stabilization.

#### Surgical vs. Conservative Management

The decision between surgical intervention and conservative management depends on the severity and trajectory of neurological deficits. Urgent transsphenoidal surgery is indicated for severe or progressive visual deficits, particularly decreasing visual acuity, and for deteriorating level of consciousness. Optimal visual outcomes are achieved when surgery is performed within the first 3 to 5 days, though intervention within 7 days is generally considered acceptable.

Conservative management is appropriate for patients with mild and stable visual deficits, isolated ocular palsies without visual acuity loss (which often recover spontaneously in 70 to 80% of cases), no visual or neurological compromise, and hemodynamic stability with adequate hormonal replacement. The UK Pituitary Apoplexy Guidelines Development Group has proposed a scoring system incorporating visual acuity, visual field defects, cranial nerve palsies, and Glasgow Coma Scale score to help standardize the surgical versus conservative management decision.

#### Outcomes

Visual improvement is achieved in 75 to 90% of patients following surgery, compared to 50 to 60% with conservative management alone. Cranial nerve palsy recovery occurs in 70 to 80% of cases regardless of the management approach chosen. Post-apoplexy hypopituitarism persists in 60 to 80% of patients, with at least one hormone deficit remaining long-term, making ACTH deficiency the most critical concern for ongoing management. Long-term follow-up includes repeat MRI at 3 to 6 months, ongoing hormonal assessment, and recognition that up to 50% of tumors show spontaneous regression following apoplexy.

<image>A clinical decision-making algorithm for pituitary apoplexy management. Start with clinical presentation (acute headache, visual changes, ophthalmoplegia). First branch: immediate actions - IV hydrocortisone 100 mg, IV fluids, STAT labs. Then imaging: CT head (rule out SAH) followed by MRI pituitary. Assessment box showing severity scoring: visual acuity, visual fields, cranial nerve palsies, GCS. Two pathways: Severe (decreasing acuity, reduced consciousness, severe field defects) leads to urgent TSS within 3-7 days; Mild/Stable (isolated CN palsy, mild field defects, stable acuity) leads to conservative management with close monitoring. Both pathways converge on long-term follow-up: hormone reassessment at 4-8 weeks, MRI at 3-6 months, lifelong hormonal monitoring. Use emergency medicine style red/yellow/green triage coloring.</image>

## Special Considerations

### Pregnancy and Hypopituitarism

Managing hypopituitarism during pregnancy requires careful attention to the physiological changes of gestation. Glucocorticoid replacement with hydrocortisone should be continued throughout pregnancy, with stress dosing during labor consisting of hydrocortisone 100 mg intravenously every 8 hours. Levothyroxine doses frequently require an increase of 30 to 50% during pregnancy, analogous to the dose adjustments needed in primary hypothyroidism. GH replacement should be discontinued when pregnancy is confirmed, as placental GH assumes the role of maternal GH production during the second and third trimesters. Desmopressin is safe during pregnancy, though doses may require upward adjustment because placental vasopressinase can increase the severity of diabetes insipidus. Achieving pregnancy in the first place requires gonadotropin therapy or pulsatile GnRH, as standard sex steroid replacement does not restore fertility.

### Adrenal Crisis Prevention

Prevention of adrenal crisis is a lifelong imperative for patients with ACTH deficiency. Comprehensive patient and family education on stress dosing rules and emergency injection technique forms the foundation of prevention. All patients should wear medical alert identification and carry an emergency hydrocortisone injection kit containing 100 mg for intramuscular administration. Training must extend to close contacts who may need to administer the injection if the patient is incapacitated. Written "sick day rules" with specific dose adjustments for various clinical scenarios should be provided and regularly reviewed. Annual assessment of adrenal crisis risk is recommended, with prior crisis identified as the strongest predictor of future episodes.

### Quality of Life in Hypopituitarism

Impaired quality of life despite seemingly adequate hormone replacement is a common and often frustrating feature of hypopituitarism for both patients and clinicians. Contributing factors include the inability of current replacement regimens to fully replicate the physiological cortisol rhythm, persistent effects of GH deficiency even when IGF-1 appears nominally normal, and chronic fatigue and cognitive impairment that do not fully resolve with standard replacement. Validated instruments such as the QoL-AGHDA (quality of life assessment of GH deficiency in adults) and AddiQoL (adrenal-specific quality of life) can help quantify these deficits and guide treatment optimization.

## Key Clinical Pearls

- Always replace cortisol BEFORE levothyroxine in newly diagnosed panhypopituitarism; levothyroxine increases cortisol clearance and can trigger adrenal crisis
- The cosyntropin stimulation test may be falsely normal in early or acute secondary adrenal insufficiency (within 2-4 weeks of pituitary insult) because adrenal atrophy has not yet developed
- In pituitary apoplexy, empiric IV hydrocortisone should be given immediately upon clinical suspicion, before confirmatory labs return
- Immune checkpoint inhibitor-induced hypophysitis: ACTH recovery is rare (~4%), TSH recovery variable (~50%), but gonadotropin recovery is common; lifelong steroid replacement usually needed
- Normal IGF-1 does NOT exclude GH deficiency in adults; dynamic testing is required unless the patient has 3+ other pituitary deficiencies and low IGF-1
- Post-radiation hypopituitarism can develop years to decades after treatment; lifelong surveillance is required even for childhood radiation

## References

1. Fleseriu M, et al. "Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2016;101(11):3888-3921.
2. Rajasekaran S, et al. "UK Guidelines for the Management of Pituitary Apoplexy." Clin Endocrinol. 2011;74(1):9-20.
3. Castinetti F, et al. "Immune Checkpoint Inhibitor-Induced Hypophysitis and Hypopituitarism." Eur J Endocrinol. 2019;181(3):107-118.
4. Schneider HJ, et al. "Hypopituitarism after Traumatic Brain Injury and Subarachnoid Hemorrhage." JAMA. 2007;298(12):1429-1438.
5. Molitch ME, et al. "Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2011;96(6):1587-1609.